Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 26, 2018
- Accepted in final form July 20, 2018
- First Published September 14, 2018.
Author Disclosures
- Andrea Marcinnò, MD*,
- Fabiana Marnetto, MSc*,
- Paola Valentino, MSc,
- Serena Martire, MSc,
- Alessia Balbo, MLT,
- Aurora Drago, MSc,
- Maria Leto, MD,
- Marco Capobianco, MD,
- Giancarlo Panzica, PhD and
- Antonio Bertolotto, MD
- Andrea Marcinnò, MD*,
NONE
NONE
(1) Mylan, funding for travel to 2017 Italian Neurology Society congress, (2) F. Hoffmann - La Roche, funding for travel to 2017 ECTRIMS-ACTRIMS joint congress
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) MD-PhD Programm, University of Turin
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fabiana Marnetto, MSc*,
NONE
NONE
1. Biogen Idec, speaker honoraria 2. Merck Serono, speaker honoraria 3. Euroimmun Italia, travel and speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Fondazione Italiana Sclerosi Multipla, grant n. 2014/R/1.
NONE
NONE
NONE
NONE
NONE
NONE
- Paola Valentino, MSc,
NONE
NONE
(1)BiogenIdec,speaker honoraria, (2)Merck Serono, speaker honoraria, (3) Novartis, speaker honoraria, (4) Euroimmun, travel grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Serena Martire, MSc,
NONE
NONE
(1) BiogenIdec, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alessia Balbo, MLT,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aurora Drago, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Leto, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marco Capobianco, MD,
Commercial entity: Biogen, Sanofi-Genzyme, Novartis, Bayer-Schering
NONE
Speaking honoraria from: Almirall, Biogen, Novartis, Sanofi-Genzyme, Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giancarlo Panzica, PhD and
NONE
NONE
NONE
Frontiers in Endocrinology - Associate Review Editor Biology of Sex Differences - Member of the Editorial Board Cell and Tissue Research - Member of the Editorial Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- University of Torino, Local Research Grants (no number) for year 2016-17-18
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Antonio Bertolotto, MD
(1)Almirall,(2)Bayer,(3)BiogenIdec, (4)Genzyme with approval by the Director of AOU San Luigi University Hospital
NONE
(1)BiogenIdec, (2)Genzyme, (3)Novartis, (4)Sanofi- Aventis, (5)Teva
(1)?Multiple Sclerosis International?, editorial Board, since 2012, (2)?Progress in Neuroscience?, editorial board, since 2012, (3)?Dataset Papers in Neuroscience?, editorial board, since 2012, (4)?Journal of Multiple Sclerosis?, editorial board, since 2014, (5)?Neurology and Therapy?, editorial board, since 2014, (6)?Multiple Sclerosis and demyelinating disorders?, editorial board, since 2015.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Merck Serono Italy, (2)Biogen, (3)Euroimmun
1)Italian Ministry of Health,RF-2013-02357497,principal investigator, 2016-2019
NONE
(1)Italian Multiple Sclerosis Foundation(FISM), 2014/PMS/1, (2)Italian Multiple Sclerosis Foundation(FISM, 2015/R/05,(3)Ricerca Biomedica ONLUS Foundation(FORB),(4)San Luigi ONLUS.
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuroscience Institute Cavalieri Ottolenghi (NICO) (A.M., P.V., S.M., A. Balbo, A. Bertolotto, F.M., G.P.), Orbassano, Turin, Italy; Neurologia–CRESM (A.M., P.V., S.M., A. Balbo, A. Bertolotto, F.M., M.C.), AOU San Luigi Gonzaga, Orbassano, Turin, Italy; “Rita Levi Montalcini” Neuroscience Department (F.M., G.P.), University of Turin, TO, Italy; and Humanitas Hospital Gradenigo (A.D., M.L.), Turin, Italy.
- Correspondence
Fabiana Marnetto fabiana.marnetto{at}gmail.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of PlasmablastsMiriam Schlüter, Eva Oswald, Stephan Winklmeier et al.Neurology: Neuroimmunology & Neuroinflammation, July 01, 2021 -
Article
Aquaporin-4 antibody titration in NMO patients treated with rituximabA retrospective studyPaola Valentino, Fabiana Marnetto, Letizia Granieri et al.Neurology: Neuroimmunology & Neuroinflammation, December 15, 2016 -
Article
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSFNora Möhn, Steffen Pfeuffer, Tobias Ruck et al.Neurology: Neuroimmunology & Neuroinflammation, December 11, 2019 -
Article
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated DiseasesAlexandre Avouac, Adil Maarouf, Jan-Patrick Stellmann et al.Neurology: Neuroimmunology & Neuroinflammation, March 15, 2021